Brought to you by

Novartis gets rights to Antisoma's AS1404 for tumors; deal ends
03 Dec 2015
Executive Summary
Novartis has licensed exclusive worldwide rights to Antisoma's (cancer therapeutics) AS1404, a vascular disrupting agent (VDA) for tumors.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Co-Promotion
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com